BioSpace News Archive

Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the launch of the AcQBlate® Force Sensing Ablation System in Europe after securing CE Mark for the company’s AcQBlate FORCE ablation catheter and the Qubic Force Sensing Module (Qubic Force).

Slayback Pharma LLC (“Slayback”) announced today the appointment of Dr Sumitra Pillai as Vice President and the new Head of R&D.

Masimo’s COVID-19 Response Efforts Highlighted at California Life Sciences Association’s Pantheon 2020 Masimo, the Only Patient Monitoring Company Included, Was One of Seven Featured California Innovators

62% overall response rate in BTK pre-treated CLL/SLL patients, rising to 84% in patients followed for 10 or more months; consistent response rates regardless of reason for prior BTK discontinuation or BTK mutation status Similar overall response rates observed in patients previously treated with all classes of available therapy (chemotherapy, anti-CD20 antibodies, BTK inhibitors, BCL2 inhibitors, PI3K-delta inhibitors) 94% of responding patients remain in response and on ther

- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular lymphoma - Fred Hutchinson preclinical models with STRO-001 identifies CD74 as a potential target for the treatment of AML

- Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted for presentation at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020) - Investor conference call and webcast scheduled for today, December 7, at 10:00 a.m. ET (7:00 a.m. PT)

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today presented clinical data on its BTK inhibitor BRUKINSA® (zanubrutinib) in two posters at the 62nd American Society for Hematology (ASH) Annual Meeting

Chimeron Bio, a leading RNA company pioneering a novel class of mRNA-based vaccines and therapeutics is pleased to announce the appointment of Dr. Antonin (Tony) de Fougerolles, CEO of Evox Therapeutics to its Scientific Advisory Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201207005690/en/ A distinguished RNA biologist, Dr. de Fougerolles has a str

CORRECTING and REPLACING CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma ACE-LY-004 Phase II trial results substantiate established efficacy and safety profile of CALQUENCE in mantle cell lymphoma

Cellworks Group , Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-021-01 clinical trial, which found that the Cellworks Omics Biology Model (CBM) predicted response to Arsenic Trioxide (ATO) and All-trans-retinoic Acid (ATRA) in Acute Promyelocytic Leukemia (APL) patients harboring PML-RARA fusions with 93% accuracy.